Randomized study evaluating the impact of an innovative and cooperative pathway integrating oncogeriatric, pharmaceutical and pharmacological follow-up in elderly patients (>70 years old) presenting with cancer and treated with oral therapy_POG
Key facts
- Where
- Bron, Caluire-et-Cuire, Chevilly-Larue, Dijon, Lille Cedex, Lyon Cedex 04, Marseille, Paris, PARIS, Paris Cedex 20, Pierre-Bénite, Rennes Cedex, Saint-Cloud, Strasbourg Cedex 2, Toulouse és Villejuif, FranciaországSee the 16 sites
- Phase
- 4. fázis
Where in Franciaország
- Hospital Femme Mere EnfantBron, FranciaországToborzás még nem indult
- Hospices Civils de Lyon_ Hôpital Fréderic DugoujonCaluire-et-Cuire, FranciaországToborzás még nem indult
- Gustave RoussyChevilly-Larue, FranciaországToborzás még nem indult
- Centr Georges Francois LeclercDijon, FranciaországToborzás még nem indult
- Centre Hospitalier Universitaire De LilleLille Cedex, FranciaországToborzás még nem indult
- Hopital De La Croix-RousseLyon Cedex 04, FranciaországToborzás még nem indult
- Hôpital La Timone - APHMMarseille, FranciaországToborzás még nem indult
- Hôpital Européen Georges PompidouParis, FranciaországToborzás még nem indult
- Hopital Cochin - Port RoyalPARIS, FranciaországToborzás még nem indult
- Hopital TenonParis Cedex 20, FranciaországToborzás még nem indult
- Hospices Civils de Lyon, Centre Hospitalier Lyon-SudPierre-Bénite, FranciaországToborzás még nem indult
- Centre De Lutte Contre Le Cancer Eugene MarquisRennes Cedex, FranciaországToborzás még nem indult
- Institut CurieSaint-Cloud, FranciaországToborzás még nem indult
- Les Hopitaux Universitaires De StrasbourgStrasbourg Cedex 2, FranciaországToborzás még nem indult
- Oncopole Claudius RegaudToulouse, FranciaországToborzás még nem indult
- Institut Gustave RoussyVillejuif, FranciaországToborzás még nem indult
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Institut Gustave Roussy
- Trial code
- EU 2025-523610-83-00
- Record updated
- 2026. szeptember 8.
- Original description
To assess the impact of reinforced multi-professional care pathway (oncologist, geriatrician, pharmacist, pharmacologist) in geriatric oncology on the occurrence of grade ≥3 non-hematologic adverse event or grade ≥4 hematologic adverse event (according to (NCI-CTCAE Version 6.0) over a maximum of 24 months in patients aged of at least 70 years and starting an oral anticancer treatment compared to usual care.Read full original descriptionShow less
Randomized study evaluating the impact of an innovative and cooperative pathway integrating oncogeriatric, pharmaceutical and pharmacological follow-up in elderly patients (>70 years old) presenting with cancer and treated with oral therapy _ POG
To assess the impact of reinforced multi-professional care pathway (oncologist, geriatrician, pharmacist, pharmacologist) in geriatric oncology on the occurrence of grade ≥3 non-hematologic adverse event or grade ≥4 hematologic adverse event (according to (NCI-CTCAE Version 6.0) over a maximum of 24 months in patients aged of at least 70 years and starting an oral anticancer treatment compared to usual care.
Inclusion: Age ≥ 70 years old; Patients must be affiliated to a social security system or beneficiary of the same; G8 score ≤14; PS ≤ 3; Follow-up for a locally advanced or metastatic solid tumor among the following: • Breast Cohort • Lung Cohort • Prostate cohort • Colon Cohort • Kidney Cohort • Sarcoma/GIST cohort; With a decision to initiate treatment with oral therapy (Tyrosine Kinase Inhibitor, Hormone Therapy) from among the following: • Breast cohort: Abemaciclib, Ribociclib, Palbociclib, Everolimus • Lung cohort: Alectinib, Brigatinib, Osimertinib • Prostate cohort: Abiraterone, Enzalutamide, Olaparib • Colon cohort: Trifluridine + Tipiracil, Capecitabine • Kidney cohort: Axitinib, Cabozantinib, Lenvatinib • Sarcoma/ GIST cohort: Sunitinib, Regorafenib, Pazopanib; Female patients must either be of non-reproductive potential or must have a negative serum pregnancy test within 14 days prior to the administration of study drug. Childbearing potential women must have agreed to use one barrier method of contraception, such as condom, plus an additional highly effective method of contraception during treatment on this trial an for up to 6 month after the last dose of study treatment; Sexually active males patients must agree to use condom during the clinical investigation and for at least 6 months after the study treatment. Also, it is recommended the childbearing potential female partner uses a highly effective method of contraception for the same duration (cf. paragraph 7.8 « Pregnancy and contraception »); Written, dated and signed informed consent by the patient prior to any specific protocol procedure; Ability to comply with the protocol procedures.
Exclusion: Patient who has already been treated or is currently being treated with the oral therapy studied; Patient who has already benefited from a pharmacological dosage for the oral therapy studied; Presence of a pathology or condition that makes the patient's participation in the study inappropriate, which includes serious unresolved or unstable toxicities from previous administration of another investigational treatment or any medical condition that could interfere with the patient safety, obtaining consent, or compliance with study procedures; Mental or psychological illness that does not allow the patient to give informed consent; Grade 3 or 4 toxicity contraindicating the implementation of oral treatment, according to the NCI-CTCAE version 6.0; Patient unable to follow the therapeutic program; Patient who has already benefited from specialized oncogeriatric care in the last 12 months; Patient under guardianship or deprived of his liberty by a judicial or administrative decision or incapable of giving its consent.